Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19465170 | 0.86 | KMT2A (0.48) | KMT2ALMNAMAPTNR1I2AHR | |
| SCHEMBL16628595 | 0.85 | KMT2A (0.46) | KMT2ALMNAMAPTNR1I2AHR | |
| SCHEMBL689466 | 0.82 | KMT2A (0.43) | KMT2ALMNAMAPTNR1I2AHR | |
| SCHEMBL16769803 | 0.82 | KMT2A (0.50) | KMT2ALMNAMAPTNR1I2AHR | |
| SCHEMBL15094633 | 0.81 | KMT2A (0.49) | KMT2ALMNAMAPTNR1I2AHR | |
| SCHEMBL29915404 | 0.81 | SLC29A1 (0.30) | MAPT | |
| SCHEMBL21979385 | 0.79 | — | — | |
| SCHEMBL29940841 | 0.79 | — | — | |
| SCHEMBL16769811 | 0.78 | KMT2A (0.37) | KMT2AMAPTCA12CA1CA2 | |
| SCHEMBL16769805 | 0.78 | KMT2A (0.37) | KMT2AMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | Mori, Kunio (JP) | 2017-11-23 | — | — | US | disclosed |
| US-9790242-B2 | Surface treatment method, surface treatment agent, and novel compound | Mori, Kunio (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9593423-B2 | Process for forming metal film, and product equipped with metal film | Mori, Kunio (JP) | 2017-03-14 | — | — | US | disclosed |
| US-9540403-B2 | Bonding method, bondability improving agent, surface modification method, surface modifying agent, and novel compound | Mori, Kunio (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160152641-A1 | BONDING METHOD, BONDABILITY IMPROVING AGENT, SURFACE MODIFICATION METHOD, SURFACE MODIFYING AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9238757-B2 | Bonding method, bondability improving agent, surface modification method, surface modifying agent, and novel compound | Mori, Kunio (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | Mori, Kunio (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20140227539-A1 | PROCESS FOR FORMING METAL FILM, AND PRODUCT EQUIPPED WITH METAL FILM | KUNIO MORI (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8753748-B2 | Process for forming metal film, and product equipped with metal film | Mori, Kunio (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20130183534-A1 | PROCESS FOR FORMING METAL FILM, AND PRODUCT EQUIPPED WITH METAL FILM | KUNIO MORI (JP) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152124-A1 | SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND | EPCAM, ITGAM, MET | KMT2A 330/4885LMNA 2695/4885MAPT 2103/4885 |
| US-20170334933-A1 | SURFACE TREATMENT AGENT AND NOVEL COMPOUND | EPCAM, MET, ITGAM | KMT2A 502/4885LMNA 1873/4885MAPT 2081/4885 |
| US-20160152641-A1 | BONDING METHOD, BONDABILITY IMPROVING AGENT, SURFACE MODIFICATION METHOD, SURFACE MODIFYING AGENT, AND NOVEL COMPOUND | NBAS, NAPA, PCNA | KMT2A 608/4885LMNA 1962/4885MAPT 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.